Last 12 months
Inside the activity.
2 purchase rows · 112 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 1 | 0 |
| Dec 2025 | 0 | 2 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 1 | 2 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 26 |
| Jun 2026 | 0 | 13 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 56 |
| Sep 2026 | 0 | 12 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 26, 2018 Filed Dec 28, 2018 22:36 UTC |
FLATLEY JAY TDirector
|
SaleCommon Stock | 3,300 | $273.87 | $903,771.00 |
DisclosureSEC source: 0001127602-18-037498 · form4.xml · nonDerivative · entry 2 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 336,579 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| December 12, 2018 Filed Dec 14, 2018 00:26 UTC |
FLATLEY JAY TDirector
|
SaleCommon Stock | 3,300 | $334.13 | $1,102,629.00 |
DisclosureSEC source: 0001127602-18-036248 · form4.xml · nonDerivative · entry 2 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 371,559 F2 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| December 12, 2018 Filed Dec 28, 2018 22:36 UTC |
FLATLEY JAY TDirector
|
GiftCommon Stock | 31,680 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-037498 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 339,879 Read SEC document |
| December 11, 2018 Filed Dec 13, 2018 23:22 UTC |
Hoyt Aimee LSVP, Chief People Officer
|
GrantPerformance Shares · Derivative | 3,421 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-036232 · form4.xml · derivative · entry 2 Hoyt Aimee L · CIK 0001727683 · SVP, Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,421 Underlying: Common Stock · 3,421 shares Expires 2022-01-02 F3 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending January 2, 2022. The number of shares issued will range from 0% to 150% of the amount specified above, based on the company's actual earnings per share for the fiscal year ending January 2, 2022, relative to pre-defined objectives, subject to awardee's continuing status as a service provider on such dates. F3 · derivative.exercise_date: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending January 2, 2022. The number of shares issued will range from 0% to 150% of the amount specified above, based on the company's actual earnings per share for the fiscal year ending January 2, 2022, relative to pre-defined objectives, subject to awardee's continuing status as a service provider on such dates. Read SEC document |
| December 11, 2018 Filed Dec 13, 2018 23:22 UTC |
Hoyt Aimee LSVP, Chief People Officer
|
GrantCommon Stock | 1,141 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-036232 · form4.xml · nonDerivative · entry 1 Hoyt Aimee L · CIK 0001727683 · SVP, Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,753 F1 · shares: Grant of restricted stock units shall vest as follows: 25% of the shares subject to the award shall vest on each of November 5, 2019, November 5, 2020, November 5, 2021 and November 5, 2022, subject to awardee's continuing status as a service provider on such dates. F2 · balance_after: Balance includes 70 shares acquired through Employee Stock Purchase Plan. Read SEC document |
| December 11, 2018 Filed Dec 13, 2018 23:18 UTC |
Dadswell CharlesSr VP & General Counsel
|
GrantPerformance Shares · Derivative | 4,561 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-036230 · form4.xml · derivative · entry 2 Dadswell Charles · CIK 0001575229 · Sr VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,561 Underlying: Common Stock · 4,561 shares Expires 2022-01-02 F2 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending January 2, 2022. The number of shares issued will range from 0% to 150% of the amount specified above, based on the company's actual earnings per share for the fiscal year ending January 2, 2022, relative to pre-defined objectives, subject to awardee's continuing status as a service provider on such dates. F2 · derivative.exercise_date: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending January 2, 2022. The number of shares issued will range from 0% to 150% of the amount specified above, based on the company's actual earnings per share for the fiscal year ending January 2, 2022, relative to pre-defined objectives, subject to awardee's continuing status as a service provider on such dates. Read SEC document |
| December 11, 2018 Filed Dec 13, 2018 23:18 UTC |
Dadswell CharlesSr VP & General Counsel
|
GrantCommon Stock | 1,521 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-036230 · form4.xml · nonDerivative · entry 1 Dadswell Charles · CIK 0001575229 · Sr VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,127 F1 · shares: Grant of restricted stock units shall vest as follows: 25% of the shares subject to the award shall vest on each of November 5, 2019, November 5, 2020, November 5, 2021 and November 5, 2022, subject to awardee's continuing status as a service provider on such dates. Read SEC document |
| December 11, 2018 Filed Dec 14, 2018 00:26 UTC |
FLATLEY JAY TDirector
|
GrantCommon Stock | 6,081 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-036248 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 374,859 F1 · shares: Grant of restricted stock units shall vest as follows: 100% of the shares subject to the award shall vest on December 11, 2019 subject to awardee's continuing status as a service provider on such date. Read SEC document |
| December 11, 2018 Filed Dec 14, 2018 00:19 UTC Amendment |
FLATLEY JAY TDirector
|
Tax withholdingCommon Stock | 4,632 | $328.90 | $1,523,464.80 |
DisclosureSEC source: 0001110803-18-000034 · primary_doc.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 368,778 F1 · date: This Form is being filed to correct the vest date and the applicable price. F1 · price: This Form is being filed to correct the vest date and the applicable price. Read SEC document |
| December 11, 2018 Filed Dec 13, 2018 23:37 UTC |
deSouza Francis ADirector · President and CEO
|
GrantPerformance Shares · Derivative | 19,383 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-036239 · form4.xml · derivative · entry 2 deSouza Francis A · CIK 0001520943 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,383 Underlying: Common Stock · 19,383 shares Expires 2022-01-02 F2 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending January 2, 2022. The number of shares issued will range from 0% to 150% of the amount specified above, based on the company's actual earnings per share for the fiscal year ending January 2, 2022, relative to pre-defined objectives, subject to awardee's continuing status as a service provider on such dates. F2 · derivative.exercise_date: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending January 2, 2022. The number of shares issued will range from 0% to 150% of the amount specified above, based on the company's actual earnings per share for the fiscal year ending January 2, 2022, relative to pre-defined objectives, subject to awardee's continuing status as a service provider on such dates. Read SEC document |
| December 11, 2018 Filed Dec 13, 2018 23:37 UTC |
deSouza Francis ADirector · President and CEO
|
GrantCommon Stock | 6,461 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-036239 · form4.xml · nonDerivative · entry 1 deSouza Francis A · CIK 0001520943 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,104 F1 · shares: Grant of restricted stock units shall vest as follows: 25% of the shares subject to the award shall vest on each of November 5, 2019, November 5, 2020, November 5, 2021 and November 5, 2022, subject to awardee's continuing status as a service provider on such dates. Read SEC document |
| December 11, 2018 Filed Dec 13, 2018 23:35 UTC |
Van Oene MarkSVP Chief Commercial Officer
|
GrantPerformance Shares · Derivative | 5,131 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-036238 · form4.xml · derivative · entry 2 Van Oene Mark · CIK 0001707477 · SVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,131 Underlying: Common Stock · 5,131 shares Expires 2022-01-02 F2 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending January 2, 2022. The number of shares issued will range from 0% to 150% of the amount specified above, based on the Company's actual earnings per share for the fiscal year ending January 2, 2022, relative to pre-defined objectives, subject to awardee's continuing to be a service provider on such dates. F2 · derivative.exercise_date: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending January 2, 2022. The number of shares issued will range from 0% to 150% of the amount specified above, based on the Company's actual earnings per share for the fiscal year ending January 2, 2022, relative to pre-defined objectives, subject to awardee's continuing to be a service provider on such dates. Read SEC document |
| December 11, 2018 Filed Dec 13, 2018 23:35 UTC |
Van Oene MarkSVP Chief Commercial Officer
|
GrantCommon Stock | 1,711 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-036238 · form4.xml · nonDerivative · entry 1 Van Oene Mark · CIK 0001707477 · SVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,784 F1 · shares: Grant of restricted stock units shall vest as follows: 25% of the shares subject to the award shall vest on each of November 5, 2019, November 5, 2020, November 5, 2021 and November 5, 2022, subject to awardee's continuing status as a service provider on such dates. Read SEC document |
| December 11, 2018 Filed Dec 13, 2018 23:34 UTC |
SAMAD SAMSr. VP and CFO
|
GrantPerformance Shares · Derivative | 4,561 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-036237 · form4.xml · derivative · entry 2 SAMAD SAMER ABDUL · CIK 0001694295 · Sr. VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,561 Underlying: Common Stock · 4,561 shares Expires 2022-01-02 F2 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending January 2, 2022. The number of shares issued will range from 0% to 150% of the amount specified above, based on the company's actual earnings per share for the fiscal year ending January 2, 2022, relative to pre-defined objectives, subject to awardee's continuing status as a service provider on such dates. F2 · derivative.exercise_date: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending January 2, 2022. The number of shares issued will range from 0% to 150% of the amount specified above, based on the company's actual earnings per share for the fiscal year ending January 2, 2022, relative to pre-defined objectives, subject to awardee's continuing status as a service provider on such dates. Read SEC document |
| December 11, 2018 Filed Dec 13, 2018 23:34 UTC |
SAMAD SAMSr. VP and CFO
|
GrantCommon Stock | 1,521 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-036237 · form4.xml · nonDerivative · entry 1 SAMAD SAMER ABDUL · CIK 0001694295 · Sr. VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,825 F1 · shares: Grant of restricted stock units shall vest as follows: 25% of the shares subject to the award shall vest on each of November 5, 2019, November 5, 2020, November 5, 2021 and November 5, 2022, subject to awardee's continuing status as a service provider on such dates. Read SEC document |
| December 11, 2018 Filed Dec 13, 2018 23:31 UTC |
Ronaghi MostafaSr VP & CTO
|
GrantPerformance Shares · Derivative | 4,561 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-036236 · form4.xml · derivative · entry 2 Ronaghi Mostafa · CIK 0001441876 · Sr VP & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,561 Underlying: Common Stock · 4,561 shares Expires 2022-01-02 F2 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending January 2, 2022. The number of shares issued will range from 0% to 150% of the amount specified above, based on the company's actual earnings per share for the fiscal year ending January 2, 2022, relative to pre-defined objectives, subject to awardee's continuing status as a service provider on such dates. F2 · derivative.exercise_date: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending January 2, 2022. The number of shares issued will range from 0% to 150% of the amount specified above, based on the company's actual earnings per share for the fiscal year ending January 2, 2022, relative to pre-defined objectives, subject to awardee's continuing status as a service provider on such dates. Read SEC document |
| December 11, 2018 Filed Dec 13, 2018 23:31 UTC |
Ronaghi MostafaSr VP & CTO
|
GrantCommon Stock | 1,521 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-036236 · form4.xml · nonDerivative · entry 1 Ronaghi Mostafa · CIK 0001441876 · Sr VP & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,133 F1 · shares: Grant of restricted stock units shall vest as follows: 25% of the shares subject to the award shall vest on each of November 5, 2019, November 5, 2020, November 5, 2021 and November 5, 2022, subject to awardee's continuing status as a service provider on such dates. Read SEC document |
| December 11, 2018 Filed Dec 13, 2018 23:30 UTC |
OSTADAN OMEADEVP Ops, Products, Strategy
|
GrantPerformance Shares · Derivative | 7,982 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-036234 · form4.xml · derivative · entry 2 OSTADAN OMEAD · CIK 0001642678 · EVP Ops, Products, Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,982 Underlying: Common Stock · 7,982 shares Expires 2022-01-02 F2 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending January 2, 2022. The number of shares issued will range from 0% to 150% of the amount specified above, based on the company's actual earnings per share for the fiscal year ending January 2, 2022, relative to pre-defined objectives, subject to awardee's continuing status as a service provider on such dates. F2 · derivative.exercise_date: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending January 2, 2022. The number of shares issued will range from 0% to 150% of the amount specified above, based on the company's actual earnings per share for the fiscal year ending January 2, 2022, relative to pre-defined objectives, subject to awardee's continuing status as a service provider on such dates. Read SEC document |
| December 11, 2018 Filed Dec 13, 2018 23:30 UTC |
OSTADAN OMEADEVP Ops, Products, Strategy
|
GrantCommon Stock | 2,661 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-036234 · form4.xml · nonDerivative · entry 1 OSTADAN OMEAD · CIK 0001642678 · EVP Ops, Products, Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,274 F1 · shares: Grant of restricted stock units shall vest as follows: 25% of the shares subject to the award shall vest on each of November 5, 2019, November 5, 2020, November 5, 2021 and November 5, 2022, subject to awardee's continuing status as a service provider on such dates. Read SEC document |
| December 11, 2018 Filed Dec 13, 2018 23:24 UTC |
MCGINNIS KAREN KVP, Chief Accounting Officer
|
GrantPerformance Shares · Derivative | 913 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-036233 · form4.xml · derivative · entry 2 MCGINNIS KAREN K · CIK 0001188264 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 913 Underlying: Common Stock · 913 shares Expires 2022-01-02 F3 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending January 2, 2022. The number of shares issued will range from 0% to 150% of the amount specified above, based on the company's actual earnings per share for the fiscal year ending January 2, 2022, relative to pre-defined objectives, subject to awardee's continuing status as a service provider on such dates. F3 · derivative.exercise_date: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending January 2, 2022. The number of shares issued will range from 0% to 150% of the amount specified above, based on the company's actual earnings per share for the fiscal year ending January 2, 2022, relative to pre-defined objectives, subject to awardee's continuing status as a service provider on such dates. Read SEC document |
| December 11, 2018 Filed Dec 13, 2018 23:24 UTC |
MCGINNIS KAREN KVP, Chief Accounting Officer
|
GrantCommon Stock | 913 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-036233 · form4.xml · nonDerivative · entry 1 MCGINNIS KAREN K · CIK 0001188264 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,240 F1 · shares: Grant of restricted stock units shall vest as follows: 25% of the shares subject to the award shall vest on each of November 5, 2019, November 5, 2020, November 5, 2021 and November 5, 2022, subject to awardee's continuing status as a service provider on such dates. F2 · balance_after: Balance includes 108 shares acquired through Employee Stock Purchase Plan. Read SEC document |
| December 11, 2018 Filed Dec 13, 2018 23:21 UTC |
Hampton Malcolm GarretEVP Clinical Genomics Group
|
GrantPerformance Shares · Derivative | 5,701 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-036231 · form4.xml · derivative · entry 2 Hampton Malcolm Garret · CIK 0001698265 · EVP Clinical Genomics Group 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,701 Underlying: Common Stock · 5,701 shares Expires 2022-01-02 F2 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending January 2, 2022. The number of shares issued will range from 0% to 150% of the amount specified above, based on the company's actual earnings per share for the fiscal year ending January 2, 2022, relative to pre-defined objectives, subject to awardee's continuing status as a service provider on such dates. F2 · derivative.exercise_date: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending January 2, 2022. The number of shares issued will range from 0% to 150% of the amount specified above, based on the company's actual earnings per share for the fiscal year ending January 2, 2022, relative to pre-defined objectives, subject to awardee's continuing status as a service provider on such dates. Read SEC document |
| December 11, 2018 Filed Dec 13, 2018 23:21 UTC |
Hampton Malcolm GarretEVP Clinical Genomics Group
|
GrantCommon Stock | 1,901 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-036231 · form4.xml · nonDerivative · entry 1 Hampton Malcolm Garret · CIK 0001698265 · EVP Clinical Genomics Group 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,101 F1 · shares: Grant of restricted stock units shall vest as follows: 25% of the shares subject to the award shall vest on each of November 5, 2019, November 5, 2020, November 5, 2021 and November 5, 2022, subject to awardee's continuing status as a service provider on such dates. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 18:59 UTC |
OSTADAN OMEADEVP Ops, Products, Strategy
|
SaleCommon Stock | 644 | $321.50 | $207,046.00 |
DisclosureSEC source: 0001127602-18-036038 · form4.xml · nonDerivative · entry 1 OSTADAN OMEAD · CIK 0001642678 · EVP Ops, Products, Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,613 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| December 06, 2018 Filed Dec 7, 2018 22:17 UTC |
Stapley MarcEVP Strategy & Corp Developmt
|
SaleCommon Stock | 200 | $333.28 | $66,656.00 |
DisclosureSEC source: 0001127602-18-035577 · form4.xml · nonDerivative · entry 6 Stapley Marc · CIK 0001539796 · EVP Strategy & Corp Developmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,957 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F5 · price: Weighted average sale price representing 200 shares sold ranging from $332.87 to $333.69 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. F6 · balance_after: Includes 1,000 shares previously held by Mr. Stapley's family trust which were transferred to Mr. Stapley and are now owned directly. Read SEC document |
| December 06, 2018 Filed Dec 7, 2018 22:17 UTC |
Stapley MarcEVP Strategy & Corp Developmt
|
SaleCommon Stock | 200 | $331.27 | $66,254.00 |
DisclosureSEC source: 0001127602-18-035577 · form4.xml · nonDerivative · entry 5 Stapley Marc · CIK 0001539796 · EVP Strategy & Corp Developmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,157 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F4 · price: Weighted average sale price representing 200 shares sold ranging from $330.89 to $331.65 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document |
| December 06, 2018 Filed Dec 7, 2018 22:17 UTC |
Stapley MarcEVP Strategy & Corp Developmt
|
SaleCommon Stock | 200 | $330.17 | $66,034.00 |
DisclosureSEC source: 0001127602-18-035577 · form4.xml · nonDerivative · entry 4 Stapley Marc · CIK 0001539796 · EVP Strategy & Corp Developmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,357 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F3 · price: Weighted average sale price representing 200 shares sold ranging from $329.80 to $330.54 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document |
| December 06, 2018 Filed Dec 7, 2018 22:17 UTC |
Stapley MarcEVP Strategy & Corp Developmt
|
SaleCommon Stock | 100 | $328.34 | $32,834.00 |
DisclosureSEC source: 0001127602-18-035577 · form4.xml · nonDerivative · entry 3 Stapley Marc · CIK 0001539796 · EVP Strategy & Corp Developmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,557 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| December 06, 2018 Filed Dec 7, 2018 22:17 UTC |
Stapley MarcEVP Strategy & Corp Developmt
|
SaleCommon Stock | 200 | $327.11 | $65,421.50 |
DisclosureSEC source: 0001127602-18-035577 · form4.xml · nonDerivative · entry 2 Stapley Marc · CIK 0001539796 · EVP Strategy & Corp Developmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,657 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F2 · price: Weighted average sale price representing 200 shares sold ranging from $326.76 to $327.455 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document |
| December 06, 2018 Filed Dec 7, 2018 22:17 UTC |
Stapley MarcEVP Strategy & Corp Developmt
|
SaleCommon Stock | 100 | $324.95 | $32,495.00 |
DisclosureSEC source: 0001127602-18-035577 · form4.xml · nonDerivative · entry 1 Stapley Marc · CIK 0001539796 · EVP Strategy & Corp Developmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,857 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| December 06, 2018 Filed Dec 7, 2018 22:14 UTC |
FLATLEY JAY TDirector
|
Tax withholdingCommon Stock | 4,632 | $334.32 | $1,548,570.24 |
DisclosureSEC source: 0001127602-18-035576 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 368,778 Read SEC document |
| December 03, 2018 Filed Dec 5, 2018 02:03 UTC |
EPSTEIN ROBERT SDirector
|
Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 1,000 | $0.00 Strike: $51.17 | $0.00 |
DisclosureSEC source: 0001127602-18-035250 · form4.xml · derivative · entry 3 EPSTEIN ROBERT S · CIK 0001252004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 1,000 shares Expires 2022-11-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| December 03, 2018 Filed Dec 5, 2018 02:03 UTC |
EPSTEIN ROBERT SDirector
|
SaleCommon Stock | 1,345 | $343.57 | $462,101.65 |
DisclosureSEC source: 0001127602-18-035250 · form4.xml · nonDerivative · entry 2 EPSTEIN ROBERT S · CIK 0001252004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,756 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| December 03, 2018 Filed Dec 5, 2018 02:03 UTC |
EPSTEIN ROBERT SDirector
|
Exercise / conversionCommon Stock | 1,000 | $51.17 | $51,170.00 |
DisclosureSEC source: 0001127602-18-035250 · form4.xml · nonDerivative · entry 1 EPSTEIN ROBERT S · CIK 0001252004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,101 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| December 03, 2018 Filed Dec 5, 2018 02:02 UTC |
deSouza Francis ADirector · President and CEO
|
SaleCommon Stock | 400 | $349.44 | $139,776.00 |
DisclosureSEC source: 0001127602-18-035249 · form4.xml · nonDerivative · entry 6 deSouza Francis A · CIK 0001520943 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,643 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F7 · price: Weighted average sale price representing 400 shares sold ranging from $349.21 to $349.98 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document |
| December 03, 2018 Filed Dec 5, 2018 02:02 UTC |
deSouza Francis ADirector · President and CEO
|
SaleCommon Stock | 400 | $348.41 | $139,364.00 |
DisclosureSEC source: 0001127602-18-035249 · form4.xml · nonDerivative · entry 5 deSouza Francis A · CIK 0001520943 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,043 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F6 · price: Weighted average sale price representing 400 shares sold ranging from $348.04 to $348.95 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document |
| December 03, 2018 Filed Dec 5, 2018 02:02 UTC |
deSouza Francis ADirector · President and CEO
|
SaleCommon Stock | 400 | $347.26 | $138,904.00 |
DisclosureSEC source: 0001127602-18-035249 · form4.xml · nonDerivative · entry 4 deSouza Francis A · CIK 0001520943 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,443 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F5 · price: Weighted average sale price representing 400 shares sold ranging from $346.83 to $347.68 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document |
| December 03, 2018 Filed Dec 5, 2018 02:02 UTC |
deSouza Francis ADirector · President and CEO
|
SaleCommon Stock | 200 | $345.84 | $69,168.00 |
DisclosureSEC source: 0001127602-18-035249 · form4.xml · nonDerivative · entry 3 deSouza Francis A · CIK 0001520943 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,843 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F4 · price: Weighted average sale price representing 200 shares sold ranging from $345.80 to $345.87 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document |
| December 03, 2018 Filed Dec 5, 2018 02:02 UTC |
deSouza Francis ADirector · President and CEO
|
SaleCommon Stock | 400 | $344.85 | $137,940.00 |
DisclosureSEC source: 0001127602-18-035249 · form4.xml · nonDerivative · entry 2 deSouza Francis A · CIK 0001520943 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,043 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F3 · price: Weighted average sale price representing 400 shares sold ranging from $344.62 to $344.99 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document |
| December 03, 2018 Filed Dec 5, 2018 02:02 UTC |
deSouza Francis ADirector · President and CEO
|
SaleCommon Stock | 1,200 | $343.78 | $412,536.00 |
DisclosureSEC source: 0001127602-18-035249 · form4.xml · nonDerivative · entry 1 deSouza Francis A · CIK 0001520943 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,443 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F2 · price: Weighted average sale price representing 1,200 shares sold ranging from $343.41 to $344.27 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document |
| December 03, 2018 Filed Dec 5, 2018 02:01 UTC |
Dadswell CharlesSr VP & General Counsel
|
SaleCommon Stock | 566 | $343.57 | $194,460.62 |
DisclosureSEC source: 0001127602-18-035248 · form4.xml · nonDerivative · entry 1 Dadswell Charles · CIK 0001575229 · Sr VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,606 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| December 03, 2018 Filed Jan 4, 2019 22:03 UTC |
EASTHAM KARINDirector
|
GiftCommon Stock | 44 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-001359 · form4.xml · nonDerivative · entry 4 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,838 Read SEC document |
| November 28, 2018 Filed Nov 30, 2018 21:24 UTC |
FLATLEY JAY TDirector
|
SaleCommon Stock | 3,300 | $321.80 | $1,061,940.00 |
DisclosureSEC source: 0001127602-18-034843 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 373,410 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| November 28, 2018 Filed Jan 4, 2019 22:03 UTC |
EASTHAM KARINDirector
|
GiftCommon Stock | 458 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-001359 · form4.xml · nonDerivative · entry 3 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,882 Read SEC document |
| November 27, 2018 Filed Jan 4, 2019 22:03 UTC |
EASTHAM KARINDirector
|
GiftCommon Stock | 315 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-001359 · form4.xml · nonDerivative · entry 2 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,340 Read SEC document |
| November 23, 2018 Filed Nov 27, 2018 21:39 UTC |
OSTADAN OMEADEVP Ops, Products, Strategy
|
SaleCommon Stock | 644 | $306.74 | $197,540.56 |
DisclosureSEC source: 0001127602-18-034486 · form4.xml · nonDerivative · entry 1 OSTADAN OMEAD · CIK 0001642678 · EVP Ops, Products, Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,257 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| November 14, 2018 Filed Nov 16, 2018 21:11 UTC |
MCGINNIS KAREN KVP, Chief Accounting Officer
|
Tax withholdingCommon Stock | 116 | $308.23 | $35,754.68 |
DisclosureSEC source: 0001127602-18-033406 · form4.xml · nonDerivative · entry 1 MCGINNIS KAREN K · CIK 0001188264 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,219 Read SEC document |
| November 14, 2018 Filed Nov 16, 2018 21:09 UTC |
FLATLEY JAY TDirector
|
SaleCommon Stock | 3,300 | $312.50 | $1,031,250.00 |
DisclosureSEC source: 0001127602-18-033404 · form4.xml · nonDerivative · entry 1 FLATLEY JAY T · CIK 0001189130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 376,710 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| November 12, 2018 Filed Nov 14, 2018 22:44 UTC |
Ronaghi MostafaSr VP & CTO
|
Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $37.04 | $0.00 |
DisclosureSEC source: 0001127602-18-033102 · form4.xml · derivative · entry 14 Ronaghi Mostafa · CIK 0001441876 · Sr VP & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2020-01-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| November 12, 2018 Filed Nov 14, 2018 22:44 UTC |
Ronaghi MostafaSr VP & CTO
|
SaleCommon Stock | 200 | $326.07 | $65,214.00 |
DisclosureSEC source: 0001127602-18-033102 · form4.xml · nonDerivative · entry 13 Ronaghi Mostafa · CIK 0001441876 · Sr VP & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,612 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.